Related Experiment Videos
Effects of TGF-beta 1 (transforming growth factor-beta 1) on the cell cycle regulation of human breast adenocarcinoma
P Mazars1, N Barboule, V Baldin
1Laboratoire de Pharmacologie et de Toxicologie Fondamentales, Toulouse, France.
Abstract:
The antiproliferative effects of TGF-beta 1 were investigated in a human breast adenocarcinoma cell line (MCF-7). We report that TGF-beta 1 inhibits proliferation through cell cycle arrest in G1. A MCF-7 cell subline (MCF-7(-)), in which the type II TGF-beta receptor is not detected, was shown to be resistant to TGF-beta 1 growth inhibitory effect. Cdk2 kinase activity was inhibited in the MCF-7 sensitive cell subline in parallel with the inhibition of cell cycle progression. In both sensitive and resistant cell lines, TGF-beta 1 treatment did not affect cdk2, cdk4, cyclin E and cyclin D1 mRNA and protein levels. However, in the MCF-7 sensitive cell subline, a time-dependent increase in cells positive for p21WAF1/CIP1 nuclear localization was observed after TGF-beta 1 treatment. These findings suggest that TGF-beta 1 inhibition of MCF-7 cell proliferation is achieved through a type II receptor-dependent down-regulation of Cdk2 kinase activity without modification of Cdk and cyclin expression, but correlated with an increase in p21WAF1/CIP1 nuclear accumulation.
Insights
Transforming growth factor-beta 1 (TGF-beta 1) inhibits breast cancer cell proliferation by arresting the cell cycle. This effect is mediated by the type II TGF-beta receptor and involves increased p21WAF1/CIP1 nuclear accumulation.
Area of Science:
- Cell Biology
- Molecular Biology
- Cancer Research
Background:
- Transforming growth factor-beta 1 (TGF-beta 1) is a key regulator of cell growth and differentiation.
- Aberrant TGF-beta signaling is implicated in various cancers, including breast adenocarcinoma.
- Understanding the mechanisms of TGF-beta 1's antiproliferative effects is crucial for cancer therapy development.
Purpose of the Study:
- To investigate the antiproliferative effects of TGF-beta 1 on human breast adenocarcinoma MCF-7 cells.
- To elucidate the molecular mechanisms underlying TGF-beta 1-induced growth inhibition.
- To determine the role of the type II TGF-beta receptor in mediating these effects.
Main Methods:
- Utilized human breast adenocarcinoma MCF-7 cell line and a resistant subline (MCF-7(-)) lacking the type II TGF-beta receptor.
- Assessed cell proliferation and cell cycle progression using flow cytometry.
- Measured Cdk2 kinase activity, and mRNA and protein levels of Cdk2, Cdk4, Cyclin E, and Cyclin D1.
- Quantified nuclear localization of p21WAF1/CIP1 using immunofluorescence.
Main Results:
- TGF-beta 1 inhibited MCF-7 cell proliferation by inducing G1 cell cycle arrest.
- MCF-7(-) cells were resistant to TGF-beta 1's growth inhibitory effects, confirming the role of the type II TGF-beta receptor.
- TGF-beta 1 treatment led to inhibition of Cdk2 kinase activity in sensitive cells.
- No significant changes in Cdk2, Cdk4, Cyclin E, or Cyclin D1 expression were observed in either cell line.
- A time-dependent increase in nuclear p21WAF1/CIP1 localization was observed in TGF-beta 1-treated sensitive cells.
Conclusions:
- TGF-beta 1 inhibits MCF-7 cell proliferation via a type II receptor-dependent pathway.
- The antiproliferative effect is mediated by down-regulation of Cdk2 kinase activity.
- This occurs without altering Cdk and cyclin expression, but is correlated with increased nuclear p21WAF1/CIP1 accumulation.